


Highlights of This Issue 1059

SPECIAL FEATURES

CCR Translations

- 1061** Establishing a Diagnostic Road Map for *MUTYH*-Associated Polyposis
Ester Borrás, Melissa W. Taggart, Patrick M. Lynch, and Eduardo Vilar
See related article, p. 1158

- 1064** Molecular Precision Chemotherapy: Overcoming Resistance to Targeted Therapies?
 Stefan Burdach
See related article, p. 1190

CCR New Strategies

- 1067** New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice
Patrick M. Forde, Ronan J. Kelly, and Julie R. Brahmer

Molecular Pathways

- 1074** Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAF^{V600E} Tumors
Meghna Das Thakur and Darrin D. Stuart


Special Report

- 1081** Turning the Tide Against Cancer Through Sustained Medical Innovation: The Pathway to Progress
Amy Abernethy, Edward Abrahams, Anna Barker, Ken Buetow, Randy Burkholder, William S. Dalton, Margaret Foti, Felix Frueh, Richard B. Gaynor, Marcia Kean, Zeba Khan, Tracy Lessor, J. Leonard Lichtenfeld, John Mendelsohn, and Laura van't Veer

Perspectives

- 1087** Aspirin and Colorectal Cancer: Back to the Future
David Tougeron, Dan Sha, Sashidhar Manthravadi, and Frank A. Sinicrope

Reviews

- 1095** Natural Killer Cells: The Secret Weapon in Dendritic Cell Vaccination Strategies
 Catharina H.M.J. Van Elssen, Tammy Oth, Wilfred T.V. Germeraad, Gerard M.J. Bos, and Joris Vanderlocht
- 1104** NSAIDs Inhibit Tumorigenesis, but How?
Evrin Gurpinar, William E. Grizzle, and Gary A. Piazza

HUMAN CANCER BIOLOGY

- 1114** LINE-1 Hypomethylation, DNA Copy Number Alterations, and *CDK6* Amplification in Esophageal Squamous Cell Carcinoma
Yoshifumi Baba, Masayuki Watanabe, Asuka Murata, Hironobu Shigaki, Keisuke Miyake, Takatsugu Ishimoto, Masaaki Iwatsuki, Shiro Iwagami, Naoya Yoshida, Eiji Oki, Kentaro Sakamaki, Mitsuyoshi Nakao, and Hideo Baba
- 1125** Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer
Darin A. Wick, John R. Webb, Julie S. Nielsen, Spencer D. Martin, David R. Kroeger, Katy Milne, Mauro Castellarin, Kwame Twumasi-Boateng, Peter H. Watson, Rob A. Holt, and Brad H. Nelson
- 1135** A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets
Sophia Adamia, Benjamin Haibe-Kains, Patrick M. Pilarski, Michal Bar-Natan, Samuel Pevzner, Herve Avet-Loiseau, Laurence Lode, Sigitas Verselis, Edward A. Fox, John Burke, Ilene Galinsky, Ibiayi Dagogo-Jack, Martha Wadleigh, David P. Steensma, Gabriela Motyckova, Daniel J. Deangelo, John Quackenbush, Richard Stone, and James D. Griffin
- 1146** MicroRNA-202-3p Inhibits Cell Proliferation by Targeting ADP-Ribosylation Factor-like 5A in Human Colorectal Carcinoma
Qifeng Wang, Zhaohui Huang, Weijie Guo, Shujuan Ni, Xiuying Xiao, Lisha Wang, Dan Huang, Cong Tan, Qinghua Xu, Ruopeng Zha, Jiwei Zhang, Weiqi Sheng, Xianghuo He, and Xiang Du

Table of Contents

- 1158** Prevalence and Characteristics of *MUTYH*-Associated Polyposis in Patients with Multiple Adenomatous and Serrated Polyps
Carla Guarinos, Miriam Juárez, Cecilia Egoavil, María Rodríguez-Soler, Lucía Pérez-Carbonell, Ramón Salas, Joaquín Cubiella, Francisco Rodríguez-Moranta, Luisa de-Castro, Luis Bujanda, Anna Serradesanferm, David Nicolás-Pérez, Maite Herráiz, Fernando Fernández-Bañares, Alberto Herreros-de-Tejada, Elena Aguirre, Judith Balmaña, María-Luisa Rincón, Angeles Pizarro, Francisco Polo-Ortiz, Adela Castillejo, Cristina Alenda, Artemio Payá, José-Luis Soto, and Rodrigo Jover
See related article, p. 1061
- 1169** Interactions of Hormone Replacement Therapy, Body Weight, and Bilateral Oophorectomy in Breast Cancer Risk
Yong Cui, Sandra L. Deming-Halverson, Alicia Beeghly-Fadiel, Loren Lipworth, Martha J. Shrubsole, Alecia M. Fair, Xiao-Ou Shu, and Wei Zheng
- 1179** Frequent Overexpression of *HMG2* in Human Atypical Teratoid/Rhabdoid Tumor and Its Correlation with *let-7a3/let-7b* miRNA
Keqiang Zhang, Hanlin Gao, Xiwei Wu, Jinhui Wang, Wendi Zhou, Guihua Sun, Jinghan Wang, Yafan Wang, Bing Mu, Charles Kim, Peiguang Chu, Donald M. Ho, David K. Ann, Tai-Tong Wong, and Yun Yen
- CANCER THERAPY: PRECLINICAL**
- 1190** Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth
Patrick J. Grohar, Laure E. Segars, Choh Yeung, Yves Pommier, Maurizio D'Incalci, Arnulfo Mendoza, and Lee J. Helman
See related article, p. 1064
- 1204** Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in *ALK*-Rearranged Non-Small Cell Lung Cancer and Predict Strategies to Overcome Resistance
Zhao Chen, Esra Akbay, Oliver Mikse, Tanya Tupper, Katherine Cheng, Yuchuan Wang, Xiaohong Tan, Abigail Altabef, Sue-Ann Woo, Liang Chen, Jacob B. Reibel, Pasi A. Janne, Norman E. Sharpless, Jeffrey A. Engelman, Geoffrey I. Shapiro, Andrew L. Kung, and Kwok-Kin Wong
- 1212** Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
Joseph D. Valentino, Jing Li, Yekaterina Y. Zaytseva, W. Conan Mustain, Victoria A. Elliott, Ji Tae Kim, Jennifer W. Harris, Katherine Campbell, Heidi Weiss, Chi Wang, Jun Song, Lowell Anthony, Courtney M. Townsend Jr, and B. Mark Evers
- 1223** Combinatorial Immunotherapy of Polyinosinic–Polycytidylic Acid and Blockade of Programmed Death-Ligand 1 Induce Effective CD8 T-cell Responses against Established Tumors
Toshihiro Nagato, Young-Ran Lee, Yasuaki Harabuchi, and Esteban Celis
- 1235** Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BE235 as a Strategy for Radiosensitization of Glioblastoma
Carlos Rodrigo Gil del Alcazar, Molly Catherine Hardebeck, Bipasha Mukherjee, Nozomi Tomimatsu, Xiaohuan Gao, Jingsheng Yan, Xian-Jin Xie, Robert Bachoo, Li Li, Amyn A. Habib, and Sandeep Burma
- 1249** Decitabine Induces Delayed Reactive Oxygen Species (ROS) Accumulation in Leukemia Cells and Induces the Expression of ROS Generating Enzymes
Tamer E. Fandy, Anchalee Jiemjit, Manjusha Thakar, Paulette Rhoden, Lauren Suarez, and Steven D. Gore
- 1259** Combined Targeting of STAT3/NF- κ B/COX-2/EP4 for Effective Management of Pancreatic Cancer
Jingjing Gong, Jianping Xie, Roble Bedolla, Paul Rivas, Divya Chakravarthy, James W. Freeman, Robert Reddick, Scott Kopetz, Amanda Peterson, Huamin Wang, Susan M. Fischer, and Addanki P. Kumar
- 1274** Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells *In Vitro* and *In Vivo*
Chun-Han Chen, Mei-Chuan Chen, Jing-Chi Wang, An-Chi Tsai, Ching-Shih Chen, Jing-Ping Liou, Shiow-Lin Pan, and Che-Ming Teng

Table of Contents

1288 **Tumorgrafts as *In Vivo* Surrogates for Women with Ovarian Cancer**



S. John Weroha, Marc A. Becker, Sergio Enderica-Gonzalez, Sean C. Harrington, Ann L. Oberg, Matthew J. Maurer, Sarah E. Perkins, Mariam AlHilli, Kristina A. Butler, Sarah McKinstry, Stephanie Fink, Robert B. Jenkins, Xiaonan Hou, Kimberly R. Kalli, Karin M. Goodman, Jann N. Sarkaria, Beth Y. Karlan, Amanika Kumar, Scott H. Kaufmann, Lynn C. Hartmann, and Paul Haluska

1323 **Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition**

Aurélien de Reyniès, Marie-Claude Jaurand, Annie Renier, Gabrielle Couchy, Ilir Hysi, Nabila Elarouci, Françoise Galateau-Sallé, Marie-Christine Copin, Paul Hofman, Aurélie Cazes, Pascal Andujar, Sandrine Imbeaud, Fabien Petel, Jean-Claude Pairon, Françoise Le Pimpec-Barthes, Jessica Zucman-Rossi, and Didier Jean

IMAGING, DIAGNOSIS, PROGNOSIS

1298 **The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer**

Martin Filipits, Torsten O. Nielsen, Margaretha Rudas, Richard Greil, Herbert Stöger, Raimund Jakesz, Zsuzsanna Bago-Horvath, Otto Dietze, Peter Regitnig, Christine Gruber-Rossipal, Elisabeth Müller-Holzner, Christian F. Singer, Brigitte Mlineritsch, Peter Dubsky, Thomas Bauernhofer, Michael Hubalek, Michael Knauer, Harald Trapl, Christian Fesl, Carl Schaper, Sean Ferree, Shuzhen Liu, J. Wayne Cowens, and Michael Gnant, for the Austrian Breast and Colorectal Cancer Study Group

1306 **Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer**

Christine M. Barnett, Michael C. Heinrich, Jeong Lim, Dylan Nelson, Carol Beadling, Andrea Warrick, Tanaya Neff, Celestia S. Higano, Mark Garzotto, David Qian, Christopher L. Corless, George V. Thomas, and Tomasz M. Beer

1313 **Ultrasound Molecular Imaging in a Human CD276 Expression-Modulated Murine Ovarian Cancer Model**

Amelie M. Lutz, Sunitha V. Bachawal, Charles W. Drescher, Marybeth A. Pysz, Jürgen K. Willmann, and Sanjiv Sam Gambhir

CANCER THERAPY: CLINICAL

1335 **Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer**



Robert Dreicer, David MacLean, Ajit Suri, Walter M. Stadler, Daniel Shevrin, Lowell Hart, Gary R. MacVicar, Omid Hamid, John Hainsworth, Mitchell E. Gross, Yuanjun Shi, Iain J. Webb, and David B. Agus

1345 **Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer**

Geert O. Janssens, Saskia E. Rademakers, Chris H. Terhaard, Patricia A. Doornaert, Hendrik P. Bijl, Piet van den Ende, Alim Chin, Robert P. Takes, Remco de Bree, Ilse J. Hoogsteen, Johan Bussink, Paul N. Span, and Johannes H. Kaanders

1355 **Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells**



Aaron P. Rapoport, Nicole A. Aqui, Edward A. Stadtmauer, Dan T. Vogl, Yin Yan Xu, Michael Kalos, Ling Cai, Hong-Bin Fang, Brendan M. Weiss, Ashraf Badros, Saul Yanovich, Gorgun Akpek, Patricia Tsao, Alan Cross, Dean Mann, Sunita Philip, Naseem Kerr, Andrea Brennan, Zhaohui Zheng, Kathleen Ruehle, Todd Milliron, Scott E. Strome, Andres M. Salazar, Bruce L. Levine, and Carl H. June

1366 **Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation**

Xin Shelley Wang, Qiuling Shi, Nina D. Shah, Cobi J. Heijnen, Evan N. Cohen, James M. Reuben, Robert Z. Orlowski, Muzaffar H. Qazilbash, Valen E. Johnson, Loretta A. Williams, Tito R. Mendoza, and Charles S. Cleeland

Table of Contents

- 1375** Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β -Glucan for High-Risk Neuroblastoma in Second or Later Remission
Brian H. Kushner, Irene Y. Cheung, Shakeel Modak, Kim Kramer, Govind Ragupathi, and Nai-Kong V. Cheung

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

- 1383** Lung Cancers with Concomitant *EGFR* Mutations and *ALK* Rearrangements: Diverse Responses to *EGFR*-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation
Jin-Ji Yang, Xu-Chao Zhang, Jian Su, Chong-Rui Xu, Qing Zhou, Hong-Xia Tian, Zhi Xie, Hua-Jun Chen, Yi-Sheng Huang, Ben-Yuan Jiang, Zhen Wang, Bin-Chao Wang, Xue-Ning Yang, Wen-Zhao Zhong, Qiang Nie, Ri-Qiang Liao, Tony S. Mok, and Yi-Long Wu

LETTERS TO THE EDITOR

- 1393** About $CD45^-/CD31^+/CD105^+$ Circulating Cells in Patients with Gynecologic Malignancies—Letter
Francesco Bertolini, Patrizia Mancuso, and John V. Heymach
- 1394** About $CD45^-/CD31^+/CD105^+$ Circulating Cells in Patients with Gynecologic Malignancies—Response
Hyun-Kyung Yu, Sun Jin Kim, and Jang-Seong Kim
- 1396** Stromal Responses among Carcinomas—Letter
Tiziana Triulzi, Rosaria Orlandi, and Elda Tagliabue
- 1397** Stromal Responses among Carcinomas—Response
Robert B. West, Matt van de Rijn, and Julia L. Chen


 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a chest coronal section of a whole body PET-CT scan from an EML4-ALK lung cancer bearing mutant mouse harboring a crizotinib resistant tumor that is subsequently treated with an HSP90 inhibitor, 17-DMAG. Complete tumor regression is observed. For details, see the article by Chen and colleagues on page 1204 of this issue.



Clinical Cancer Research

20 (5)

Clin Cancer Res 2014;20:1059-1397.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/20/5>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/20/5>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.